| 产品描述: | Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC50 = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine -induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT. |
| 体外研究: |
Upacicalcet (0.3-30 mg/kg,静脉注射,一次) sodium 可降低雄性 SD 大鼠和双肾切除 SD 大鼠血清 iPTH、Ca2+ 和 Pi 水平,不影响雄性 SD 大鼠的胃排空[1]。 Upacicalcet (0.2-1 mg/kg,静脉注射,每周三次,三周) sodium 可降低 Adenine 诱导的 CKD SD 大鼠模型血清 iPTH 水平,并抑制甲状旁腺增生[2]。 Upacicalcet (1 mg/kg,皮下注射,每日一次,28 天) sodium 可降低 Adenine 诱导的 CKD Wistar 大鼠模型血清 iPTH 水平,并抑制异位钙化和皮质孔洞形成[2]。 |
| 体内研究: |
Upacicalcet (0.0001-10 μM) sodium 在 1.2 mM Ca2+ 存在的情况下,在表达人类 CaSR 的 HEK293T (CaSR-HEK) 细胞中可增加细胞内 Ca2+ 和 IP-1 (EC50 = 26.1 nM)。 |
| 参考文献: |
1. Goto M, et al. Pharmacological profile of upacicalcet, a novel positive allosteric modulator of calcium-sensing receptor, in vitro and in vivo. Eur J Pharmacol. 2023 Oct 5;956:175936. 2. Sato H, et al. Upacicalcet, a positive allosteric modulator of the calcium-sensing receptor, prevents vascular calcification and bone disorder in a rat adenine-induced secondary hyperparathyroidism model. Bone. 2023 Feb;167:116613. |
| 保存条件: |
-80°C 6个月; -20°C 1个月, 干燥 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.676 ml |
13.378 ml |
26.756 ml |
| 5 mM |
0.535 ml |
2.676 ml |
5.351 ml |
| 10 mM |
0.268 ml |
1.338 ml |
2.676 ml |
| 50 mM |
0.054 ml |
0.268 ml |
0.535 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |